A multiparametric prostate MRI report is mainly designed to estimate whether there is a suspicious focus of clinically significant prostate cancer and to map its location. The report usually includes prostate volume, lesion location and size, PI-RADS score, diffusion restriction/ADC findings, T2 appearance, contrast enhancement and signs of spread outside the prostate. PI-RADS 1-2 is relatively reassuring, 3 is indeterminate, and 4-5 is increasingly suspicious, but MRI is not a biopsy: cancer can be missed and a suspicious lesion still requires tissue confirmation when the overall risk justifies biopsy.

Why prostate MRI is performed

MRI is commonly used before biopsy in men with suspected organ-confined prostate cancer. It can target suspicious areas, reduce unnecessary biopsy in selected low-risk men and provide local staging information. It is also used in active surveillance and after prior negative biopsy in appropriate cases.

Prostate volume and PSA density

MRI calculates prostate volume in mL/cc. PSA density is total PSA divided by this volume. A PSA of 6 ng/mL with a 60 mL prostate gives a PSAD of 0.10 ng/mL/cc. PSA density helps distinguish PSA elevation explained by benign gland size from disproportionate elevation, although no single cutoff works in every situation.

How lesions are described

Zone and sector

The prostate has peripheral and transition zones. Reports may identify a lesion by sector, for example right posterolateral peripheral zone at the mid gland. This mapping allows MRI-targeted biopsy.

T2-weighted appearance

T2 imaging shows prostate anatomy. A focal low-signal lesion can be suspicious, but benign prostatic hyperplasia and inflammation may mimic cancer, particularly in the transition zone.

Diffusion and ADC

Clinically significant cancers often restrict water diffusion: they appear bright on high-b-value diffusion images and dark on the ADC map. Stronger restriction generally increases suspicion.

Dynamic contrast enhancement

Early focal enhancement can support suspicion, especially in peripheral-zone lesions, but it has a secondary role in PI-RADS v2.1 compared with diffusion and T2 features.

PI-RADS score

PI-RADS standardises the probability that a lesion represents clinically significant cancer: 1 very low, 2 low, 3 intermediate/indeterminate, 4 high and 5 very high. The score is an imaging probability category, not the cancer grade or stage.

Signs of local spread

The report may comment on capsular contact, extracapsular/extraprostatic extension, neurovascular bundle involvement and seminal-vesicle invasion. These findings matter for staging and surgical/radiotherapy planning but have imperfect sensitivity, particularly for microscopic extension.

Lymph nodes and bones

Pelvic nodes and visible bones are reviewed, but a prostate MRI is not a complete whole-body staging test. Small metastatic nodes can appear normal by size, and suspicious findings may lead to PSMA PET/CT, CT or bone imaging depending on cancer risk and local practice.

What happens after the MRI?

Biopsy decisions combine PI-RADS, PSA density, examination, family/genetic risk and previous biopsy history. EAU guidance supports MRI before biopsy and MRI-targeted sampling for suspicious lesions. In selected men with PI-RADS 1-2 and low clinical suspicion, biopsy may be deferred with PSA monitoring.

MRI quality and why expert review sometimes matters

PI-RADS assumes adequate multiparametric MRI technique. Motion, hip implants, rectal gas, haemorrhage soon after biopsy and suboptimal diffusion images can reduce confidence. The report may state that the study is technically limited. A low-suspicion score on a poor-quality scan should not be treated as equivalent to a high-quality negative MRI.

When biopsy and MRI disagree—for example, a PI-RADS 5 lesion with repeatedly benign sampling—multidisciplinary review of both images and pathology can be useful before either dismissing the MRI or repeating procedures blindly.

Read a prostate MRI report in this order

Start with prostate volume and PSA density, then identify the index lesion: its zone, side, level and size. Next read the sequence-specific description and PI-RADS category. Only after that look for staging features such as capsular contact/extraprostatic extension, seminal-vesicle invasion, nodes and bone lesions. This separates ‘is there a suspicious focus?’ from ‘if cancer is present, does MRI suggest local spread?’.

MRI quality matters. Motion, post-biopsy haemorrhage, hip metalwork, rectal gas and suboptimal diffusion images can reduce confidence. When the scan will determine whether and where to biopsy, expert re-review can be valuable if the images and clinical picture do not match.

What the staging phrases on prostate MRI mean

Radiologists may describe broad capsular contact, capsular bulge, irregular capsule or measurable extraprostatic extension. These phrases do not all carry the same certainty. Seminal-vesicle invasion is a separate staging feature and should not be inferred merely from a lesion being near the prostate base.

Nodes are assessed mainly by size and morphology on conventional MRI, which is imperfect for microscopic nodal disease. Likewise, a routine prostate MRI field of view is not a complete metastatic survey. If cancer is subsequently shown to be high risk, staging may require PSMA PET/CT or other appropriate imaging depending on availability and guideline pathway.

This is why a prostate MRI report has two layers: lesion detection for biopsy and local staging for treatment planning. The first layer is dominated by PI-RADS; the second uses anatomical signs of spread.

What to bring for consultation

• MRI images and report.
• Current and previous PSA values.
• Prostate volume and calculated PSA density if available.
• Previous biopsy/HPE reports.
• Family history and prostate-cancer genetic testing if relevant.

FAQs

Related reading

• PI-RADS Score on MRI Explained
• PSA Report Explained
• Free PSA vs Total PSA Report Explained
• HPE / Biopsy Report Explained
• Cancer Staging Report Explained
• Urologist in Latur

References

• European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026 https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
• American College of Radiology. Prostate Imaging Reporting & Data System (PI-RADS), version 2.1 https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/PI-RADS